Status:
COMPLETED
Proteomic Study of Chuanhong Zhongfeng Capsule in the Treatment of ACI
Lead Sponsor:
Yingyue Ding
Conditions:
Acute Ischemic Stroke
Eligibility:
All Genders
40-80 years
Phase:
PHASE1
Brief Summary
Acute cerebral infarction is characterized by high disability rate and high recurrence rate, which poses a great threat to the life and health of the nation. Proteomics technology is a holistic and co...
Eligibility Criteria
Inclusion
- Meet the diagnostic criteria for ischemic stroke in the Chinese Guidelines for Diagnosis and Treatment of Ischemic Stroke in the Acute Phase 2018.
- Meet the diagnostic criteria for ischemic stroke in Chinese medicine.
- Within 2 weeks of acute onset of ischemic stroke.
- 4 ≤ NIHSS score \<15.
- Age 40-80 years old. -
Exclusion
- Diagnosis of hemorrhage or other pathological brain disorders based on head CT or MRI;
- Allergic individuals, those who are allergic to the test medication or the associated medicinal flavors or components thereof;
- Age \<40 years or \>80 years;
- Those with severe liver or kidney function impairment. -
Key Trial Info
Start Date :
January 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2025
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT06874140
Start Date
January 1 2022
End Date
January 1 2025
Last Update
March 13 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Changchun, China